Asset Details
Do you wish to reserve the book?
Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers
Do you wish to request the book?
Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers
2012
Overview
Hepcidin regulates plasma iron bioavailability and subsequently iron availability for erythropoiesis. rHuEPO has been reported to decrease hepcidin expression in case of repeated subcutaneous injections. Thus, hepcidin level measurement could be a candidate marker for detection of rHuEPO abuse. However, when used for doping, rHuEPO can be injected intravenously and the scheme of injection is unknown. Our aim was to evaluate the early effects of a single intravenous rHuEPO injection on serum hepcidin levels. Fourteen male healthy volunteers received one intravenous injection of 50 U/Kg of rHuEPO during a placebo-controlled, randomized, double-blind, cross-over study. Serum hepcidin, quantified by a competitive ELISA method and iron parameters was then evaluated for 24 h. Serum levels of hepcidin were significantly increased 4 h after rHuEPO injection when compared with placebo injection (78.3 ± 55.5 vs. 57.5 ± 34.6 ng/ml, respectively; +36%,
p
< 0.05), whereas iron and transferrin saturation dramatically decreased 12 h after rHuEPO injection when compared with placebo injection (9.2 ± 3.5 vs. 15.8 ± 4.2 μg/l, respectively; −42%,
p
< 0.05 and 14.8 ± 5.0 vs. 26.3 ± 6.4%, respectively; −44%,
p
< 0.05). In addition, 12 and 24 h after rHuEPO injection serum hepcidin levels were lower compared with placebo injection (41.6 ± 27.4 vs. 56.6 ± 28.1 ng/ml after 12 h; −27%,
p
< 0.05 and 26.0 ± 29.6 vs. 81.2 ± 29.4 ng/ml after 24 h; −68%,
p
< 0.05). Intravenous injection of recombinant EPO induces a precocious and transient increase of serum hepcidin leading to a transient decrease of iron bioavailability. The transitory increase and dynamics of its concentration make difficult the practical use of hepcidin to detect rHuEPO doping.
Publisher
Springer-Verlag,Springer,Springer Nature B.V,Springer Verlag
Subject
/ Anemia
/ Antimicrobial Cationic Peptides
/ Antimicrobial Cationic Peptides - blood
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Enzyme-Linked Immunosorbent Assay
/ Erythropoietin - administration & dosage
/ France
/ Fundamental and applied biological sciences. Psychology
/ Growth Differentiation Factor 15
/ Growth Differentiation Factor 15 - blood
/ Hematinics - administration & dosage
/ Humans
/ Hépatology and Gastroenterology
/ Iron
/ Iron-Binding Proteins - blood
/ Liver
/ Male
/ Occupational Medicine/Industrial Medicine
/ Placebos
/ Receptors, Cell Surface - blood
/ Recombinant Proteins - administration & dosage
/ Vertebrates: body movement. Posture. Locomotion. Flight. Swimming. Physical exercise. Rest. Sports
